Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $39.50.

BHVN has been the subject of a number of recent research reports. Morgan Stanley increased their price objective on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, September 25th. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. BidaskClub downgraded shares of Biohaven Pharmaceutical Holding Co from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/biohaven-pharmaceutical-holding-co-ltd-bhvn-given-average-rating-of-buy-by-brokerages.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $214,000. Strs Ohio acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $680,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $374,000.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 32.08 on Monday. The company’s market capitalization is $1.15 billion. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $39.51. The stock has a 50 day moving average price of $34.63 and a 200 day moving average price of $28.21.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.